**Copyright Information of the Article Published Online**

|  |  |
| --- | --- |
| **TITLE** | Nutrition status and Helicobacter pylori infection in patients receiving hemodialysis |
| **AUTHOR(s)** | Mitsushige Sugimoto, Hideo Yasuda and Akira Andoh |
| CITATION | Sugimoto M, Yasuda H, Andoh A. Nutrition status and Helicobacter pylori infection in patients receiving hemodialysis. World J Gastroenterol 2018; 24(15): 1591-1600 |
| URL | http://www.wjgnet.com/1007-9327/full/v24/i15/1591.htm |
| DOI | http://dx.doi.org/10.3748/wjg.v24.i15.1591 |
| OPEN ACCESS | This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| CORE TIP | Hemodialysis (HD) patients have a poor prognosis related in part to protein-energy wasting (PEW), associated with low levels of ghrelin. The severity of gastric mucosal atrophy has been suggested as the major determinant of ghrelin levels. Eradication of Helicobacter pylori (H. pylori) improves nutritional status, with serum cholinesterase and cholesterol levels stimulated by rising ghrelin levels and appetite, especially in H. pylori infection-positive patients with severe gastric mucosal atrophy. Although infection rates of H. pylori have been decreasing in HD patients, it would be preferable to eradicate H. pylori promptly before progression of gastric atrophy for prevention of gastric cancer and PEW. |
| KEY WORDS | Helicobacter pylori, Hemodialysis, Ghrelin, Gastric mucosa, and Anti-bacterial agents |
| COPYRIGHT  | © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| NAME OF JOURNAL | World Journal of Gastroenterology |
| ISSN | 1007-9327 |
| PUBLISHER | Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA |
| WEBSITE | Http://www.wjgnet.com |

Ms. wjg/20XX REVIEW

Nutrition status and *Helicobacter pylori* infection in patients receiving hemodialysis

Mitsushige Sugimoto, Hideo Yasuda, Akira Andoh

Mitsushige Sugimoto, Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Shiga 520-2192, Japan

Hideo Yasuda, First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan

Akira Andoh, Department of Gastroenterology, Shiga University of Medical Science Hospital, Shiga 520-2192, Japan

Author contributions: Sugimoto M, Yasuda H and Andoh A wrote the paper.

Correspondence to: Mitsushige Sugimoto MD, PhD, Associate Professor, Division of Digestive Endoscopy, Shiga University of Medical Science Hospital, Seta Tsukinowa-cho, Shiga 520-2192, Japan. sugimo@belle.shiga-med.ac.jp

Telephone: +81-77-5482618 Fax: +81-77-5482618

Received: February 23, 2018 Revised: March 18, 2018 Accepted: March 25, 2018

Published online: April 21, 2018

**Abstract**

Chronic kidney disease (CKD) patients receiving hemodialysis (HD) often develop gastrointestinal abnormalities over their long treatment period. In general, prognosis in such patients is poor due to the development of protein-energy wasting (PEW). Therefore, it is important to clarify the etiology of PEW and to establish better strategies to deal with this condition. Chronic *Helicobacter pylori* (*H. pylori*) infection in the gastric mucosa has a close association with not only the development of peptic ulcer disease and gastric cancer, but is also associated with abnormal plasma and gastric mucosal ghrelin levels that are seen in malnutrition. It is unclear whether *H. pylori* infection of the gastric mucosa is directly associated with prognosis in HD patients by affecting ghrelin levels. Recent studies show that the prevalence of *H. pylori* infection in HD patients is significantly lower than in subjects with normal renal function. In the natural history of *H. pylori* infection in HD patients, the prevalence of infection decreases as the length of time on HD increases. The severity of gastric mucosal atrophy has been suggested as the major determinant of ghrelin levels in these patients, and eradication therapy of *H. pylori* improves nutritional status by increasing serum cholinesterase and cholesterol levels, especially in patients with mild-to-moderate gastric mucosal atrophy. Prompt *H. pylori* eradication to inhibit the progress of gastric atrophy may be required to prevent this decrease in ghrelin levels and subsequent PEW and improve the prognosis of HD patients by improving their nutritional status.

**Key words:** *Helicobacter pylori*; Hemodialysis; Ghrelin; Gastric mucosa; Anti-bacterial agents

Sugimoto M, Yasuda H, Andoh A. Nutrition status and *Helicobacter pylori* infection in patients receiving hemodialysis. *World J Gastroenterol* 2018; 24(15): 1591-1600 Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i15/1591.htm DOI: http://dx.doi.org/10.3748/wjg.v24.i15.1591

**Core tip:** Hemodialysis (HD) patients have a poor prognosis related in part to protein-energy wasting (PEW), associated with low levels of ghrelin. The severity of gastric mucosal atrophy has been suggested as the major determinant of ghrelin levels. Eradication of *Helicobacter pylori* (*H. pylori*) improves nutritional status, with serum cholinesterase and cholesterol levels stimulated by rising ghrelin levels and appetite, especially in *H. pylori* infection-positive patients with severe gastric mucosal atrophy. Although infection rates of *H. pylori* have been decreasing in HD patients, it would be preferable to eradicate *H. pylori* promptly before progression of gastric atrophy for prevention of gastric cancer and PEW.

INTRODUCTION

With ongoing progress in medical and dialysis machine techniques, the number of chronic renal failure patients receiving hemodialysis (HD) is increasing at a rate of 7% per year. At least 2.9 million Asians require dialysis, including Japanese, who live in an aging society and experience changes in their living environment[1,2]. HD patients often experience gastrointestinal symptoms (*e.g.*, nausea, abdominal pain, and constipation) caused by elevated urea levels, decreased gastrointestinal motility, amyloid protein deposition, and sensory dis­turbances, and are at increased risk of developing gastrointestinal diseases (*e.g.*, peptic ulcer disease, gastric antral vascular ectasia, gastroesophageal reflux disease, and gastric cancer)[3-7]. The risk of gastric mucosal damage is elevated in this population, in association with high ammonia levels[8], systemic and/or local chronic circulatory failure[9,10], and hyperga­strinemia[11]. Gastroduodenal diseases such as peptic ulcer and gastric cancer have been linked to chronic *Helicobacter pylori* (*H. pylori*) infection[12-15]. In HD patients, the role of chronic *H. pylori* infection in their prognosis and quality of life (QOL) has not been defined.

In general, QOL in HD patients is poor. This affects their nutritional status, and thereby contributes to the development of malnutrition, which is a potent predictor of morbidity and mortality[16,17]. The state of metabolic and nutritional derangement called protein-energy wasting (PEW) has a major impact on mortality in HD patients[16,17]. Improving the prognosis of HD patients with PEW requires determination of its etiology and the development of prophylactic strategies[18,19].

The complex interactions of gastroduodenal disease, nutritional status, and *H. pylori* infection in HD patients (which tends to decrease with increasing time on dialysis[20]) remain to be elucidated. Here, we review the association between *H. pylori* infection and HD, and the relationship between *H. pylori* and nutritional status in this population. Finally, we review the effects of *H. pylori* eradication therapy in *H. pylori*-positive HD patients on nutritional status and plasma ghrelin levels.

*H. pylori* INFECTION IN HD PATIENTS

*H. pylori* is a spiral-shaped, microaerophilic Gram-negative flagellate bacterium isolated in 1983 from gastric biopsy specimens of patients with chronic atrophic gastritis[21]. The gastric mucosa of approximately 50% of the world’s population is infected with *H. pylori*, and the infection levels exceed 70% in some developing areas[15,22-24].

Previously, we reported that the prevalence of *H. pylori* infection in 539 Japanese HD patients with a mean treatment period of 8.4 ± 0.3 year in 1997 was 48.6% (95%CI: 44.3%-52.9%). This was significantly lower than that in dyspepsia patients with normal renal function [78.5% (74.1%-82.4%), *P* < 0.001] and individuals receiving annual health checks [69.4% (60.3%-77.5%), *P* < 0.001][20]. In a meta-analysis of reports investigating the prevalence of *H. pylori* in dialysis patients before 2009, the prevalence in patients receiving HD and continuous ambulatory peritoneal dialysis (CAPD) was 43.9% [(95%CI: 42.2%-45.6%), 1435/3272] and 34.8% [(29.6%-40.2%), 113/325], respectively, which was again significantly lower than that in individuals with normal renal function [49.8% (48.0%-51.7%), 1476/2961, *P* < 0.001][25]. Although infection rates differ among different geo­graphic populations, in East Asian countries where the prevalence of *H. pylori* infection and incidence of gastric cancer is relatively high, the latest statistics show the infection rate in HD patients to be 44.5% (41.55%-47.6%, 474/1065), which is significantly lower than that in individuals with normal renal function [54.0% (50.9%-57.1%), 560/1038, *P* < 0.001][25]. Importantly, the prevalence in individuals with normal renal function is similar in patients receiving HD treatment for < 1 year[20]. HD treatment, but not uremia from chronic renal failure, may play an important role in the decreased prevalence of *H. pylori* infection.

Recently, infection rates of *H. pylori* have been decreasing. A large-scale Japanese epidemiological study showed that the infection rate in Japanese has declined to 30%-50%, especially in younger patients[26]. Supporting this phenomenon, an investigation of 500 Japanese HD patients with a mean treatment duration of 6.9 ± 6.6 years (2015) reported that the prevalence of infection had dramatically decreased, to 15.0% (95%CI: 12.0-18.4)[27]. Although it has not yet been proven, decreasing rates of *H. pylori* infection suggest that the incidence of peptic ulcer disease and gastric cancer is expected to be decreasing in HD patients and that QOL in HD patients has improved due to decreases in *H. pylori-*related gastrointestinal disease.

TREATMENT PERIODS OF HD AND *H. PYLORI* INFECTION

There is an inverse relationship between *H. pylori* infection and dialysis treatment duration (Table 1)[20,27-31]. We showed that the duration of HD treatment in *H. pylori-*positive patients was 4.6 ± 3.8 years, which is significantly shorter than that in *H. pylori-*negatives (7.3 ± 6.9 years, *P* = 0.001)[27]. Interestingly, the finding of decreased *H. pylori* infection is characteristic of the prevalence of infection decreasing when the treatment period is ≥ 2 year[28], and the infection rate gradually decreases up to four years after the initiation of HD and is followed by a plateau[20]. In a 4-year follow-up survey of *H. pylori-*positive patients, the prevalence of infection was 51.6% at 1 year, 42.9% at 2 year, and 38.3% at 4 year in the absence of eradication therapy. In other words, 26.7% of patients were naturally cured of *H. pylori* infection over four years[20].

It is unknown why HD patients have a lower pre­valence of *H. pylori* infection. One hypothesis is that HD patients have higher levels of pro-inflammatory cytokines[32]. As a result, gastric atrophy progresses, and finally *H. pylori* are not able to live in the gastric mucosa[33-35]. Another hypothesis is that elevated blood urea and urea nitrogen levels may inhibit *H. pylori* growth[36]. A third hypothesis is that *H. pylori* may be cured with incidental antibiotic treatment, because most HD patients suffer from an increased incidence of bacterial infections, and because plasma levels of antimicrobial agents may be higher in HD patients than in individuals with normal renal function[37].

PEPSINOGEN IN HD PATIENTS

Human pepsinogens (PGs) are proenzymes that act on pepsin. Serum PG levels reflect the status of the gastric mucosa, and decreased PG secretion is a marker of gastric mucosal atrophy. In patients without renal dysfunction, measurements of serum PG levels are used in screening for gastric cancer and gastric mucosal atrophy[38]. In addition, serum PG levels and the PG I/PG II ratio are useful in determining the level of gastric acid secretion[39]. Recently in Japan, a combination of the serum PG level and *H. pylori*-IgG level, namely the ABC method, has been commonly used at health screenings as a useful marker for gastric cancer[40]. Because PG is eliminated *via* the kidney, serum PG levels are elevated in patients with renal dysfunction[41]. The value of serum PG levels as a biomarker of gastric atrophy and the capacity of gastric acid secretion in HD patients was heretofore unknown.

A recent report has demonstrated that PG I and II levels and PG I/PG II ratios in *H. pylori*-negative HD patients are significantly higher than those in *H. pylori*-positives and that PG I levels positively correlate with PG II levels and PG I/PG II ratio in *H. pylori-*negative HD patients (|R| = 0.849 and |R| = 0.569), past-infection patients (|R| = 0.870 and |R|=0.575) and current-infection patients (|R| = 0.784 and |R| = 0.517)[26,42]. In addition, a receiver operating characteristic curve using a cut-off value of 7.75 demonstrated that the sensitivity and specificity of PG I/PG II ratio in predicting the absence of *H. pylori* were 88.7% and 84.0%, respectively[26]. Therefore, serum PG I/PG II ratio may be a valid marker for *H. pylori* infection status and gastric mucosal atrophy in HD patients. Further large-scale studies are needed to verify this.

NECESSITY OF *H. PYLORI* ERADICATION THERAPY FOR HD PATIENTS

The incidence rates of peptic ulcer and gastric cancer in HD patients are higher than those in individuals with normal renal function[7,43]. In addition, because most HD patients receive anti-thrombotic therapy and/or non-steroidal anti-inflammatory drugs (NSAIDs), the development of drug-induced ulcers and hemorrhage from gastroduodenal lesions easily occurs and often causes fatal blood loss. Therefore, prompt *H. pylori* eradication therapy is necessary for *H. pylori*-infected HD patients[12,13], especially in HD patients with a higher risk of disease development, such as those with a past history of peptic ulcer, gastroduodenal hemorrhage, or use of anticoagulants and/or NSAIDs.

To reduce the risk of gastric cancer, the Japanese health insurance system in 2012 began covering *H. pylori* eradication therapy for all patients with endoscopic gastritis as well for peptic ulcers, gastric mucosa-associated-lymphoid tissue (MALT) lymphoma, post-endoscopic resection of early gastric cancer, and idiopathic thrombocytopenic purpura (ITP)[44-49]. In Japan, first-line eradication therapy is limited to a regimen that employs a standard dose of vonoprazan or proton pump inhibitor (PPI) administered twice daily, amoxicillin (AMPC) 750 mg twice daily, and clarithromycin (CAM) 200 mg or 400 mg twice daily for 1 wk. Unfortunately, because the prevalence of CAM-resistant *H. pylori* strains in Japan is increasing (> 30%), the eradication rate is gradually decreasing[14,50-53]. Eradication therapy is more challenging in HD patients since they have many exposures to antimicrobial agents due to immune system impairment[54,55]. In fact, 36.4% of patients with chronic renal failure are reported to be infected with CAM-resistant strains, which is significantly higher than in patients with normal renal function (15.2%)[54]. Our recent data published in 2017 shows that rate of CAM-resistant strains in HD patients is 40.5% of infected patients[55]. Alternative regimens may be designed to use *H. pylori-*susceptible antimicrobial agents, increased dosages of antimicrobial agents and PPIs, increased dosing frequency, and longer treatment periods, according to international treatment guidelines[13,52,56-60].

There is no optimal *H. pylori* eradication regimen in HD patients yet (Table 2). Some antimicrobial agents, especially AMPC, are known to exacerbate renal dysfunction. The maximum drug concentration of AMPC in patients with renal failure is 2-4 times higher than in patients with normal renal function, and the half-life is 5-20 times as long as that in healthy individuals[37].Although several previous reports showed no severe adverse effects of AMPC in HD patients receiving eradication therapy[4,11,30,61-65], the Japanese guidelines for *H. pylori* eradication therapy in the Japanese Society of Helicobacter Research recommends a reduction in AMPC dosage for HD patients[12] and the Japanese drug prescribing guidelines accordingly recommend that the dosage of AMPC for patients with renal failure should be reduced by 70%.In fact, the toxic effects of AMPC in HD patients have been reported in various studies[66-68]; for example, Sheu *et al*[68] reported that patients with a lansoprazole-CAM-metronidazole regimen had a lower risk of acute renal failure than those with a lansoprazole-CAM-AMPC regimen (2% *vs* 18%; relative risk, 0.128, 95%CI: 0.016-0.979) for chronic renal failure non-dialysis patients. Overdose of drugs has to be carefully prevented. Although an optimal regimen for dosage and periods of AMPC in HD patients is not described in the Japanese guidelines for eradication[12], an AMPC-reduced regimen may be appropriate in HD patients.

Recently, we have adopted a regimen composed of PPI and CAM, both at conventional dosage, and a dose of AMPC that is one-third of the conventional dosage (250 mg twice daily), and investigated the efficacy and safety of this regimen[55]. This regimen in HD patients provided equivalent efficacy as the standard dose in conventional therapy for non-dialysis patients in Japan (82.4% and 82.4%, respectively)[55]. Although this suggests that AMPC-reduced triple therapy is effective and safe for HD patients[55,69,70], the sample number of these reports is small, and it is necessary to set an optimal regimen in HD using a larger number of subjects.

Although the eradication rate with the Japanese standard triple therapy was first reported as appro­ximately 85%-91%, it has gradually decreased year by year because of increased prevalence of CAM-resistant strains of *H. pylori*. Because the eradication rates with tailored treatments based only on CAM susceptibility are not very high (71.9%-94.3%), more advanced tailored treatment considering other factors (*e.g.*, different doses of antibiotics and PPIs, different dosages and treatment period) are required to achieve high eradication rates. A tailored *H. pylori* eradication regimen based on CAM susceptibility and maintaining acid secretion (rabeprazole, 10 mg, q.i.d.) is useful because it can achieve an eradication rate exceeding 95%, irrespective of eradication history, thus overcoming differences among CYP2C19 genotypes[52]. However, there was no report to investigate efficacy of tailored regimen in HD patients.

*H. PYLORI* INFECTION AND NUTRITION STATUS IN HD PATIENTS

HD patients have many risk factors that affect mortali­ty, such as chronic inflammation and metabolic and nutritional derangement[16,17,71]. PEW is defined as a state of decreased body stores of protein and energy fuels (body protein and fat mass) and is diagnosed if three features are present: (1) Abnormal nutrition markers (*i.e.*, low serum levels of albumin, transthyretin or cholesterol); (2) reduced body mass (*i.e.*, low or reduced body or fat mass or weight loss with reduced intake of protein and energy); and (3) reduced muscle mass (*i.e.*, muscle wasting or sarcopenia, and reduced mid-arm muscle circumference)[72].

Ghrelin, an orexigenic peptide released primarily from endocrine cells in the stomach, is important in the pathogenesis of PEW in HD patients[71,73,74]. Ghrelin has multiple functions, including enhancement of the orexigenic effect, protein anabolism, anti-inflammatory action, and cardiovascular protection[74,75,76]. Plasma ghrelin levels increase after fasting and decrease after eating. Ghrelin levels are elevated in patients with a lean body[77]. Plasma ghrelin levels have been found to be associated with malnutrition in patients with advanced-stage cancer and anorexia nervosa[76]. In HD patients, a low ghrelin level increases the risk of cardiovascular mortality and morbidity[78], and the utility of monitoring plasma ghrelin at fixed intervals has been proven as a biomarker for mortality in HD patients[71].

*H. pylori* infections affect ghrelin levels. *H. pylori*-positive patients have lower gastric mucosal and plasma ghrelin levels and a smaller population of ghrelin-positive cells in the gastric mucosa[79]. Although subjects with normal renal function show a correlation between plasma ghrelin level and the severity of gastric mucosal atrophy[79], the association between ghrelin and *H. pylori* infection and between ghrelin and gastric mucosal atrophy in HD patients is less well understood. In an analysis using 78 HD patients and 51 non-dialysis patients with chronic renal disease, des-acyl ghrelin levels in HD patients were significantly higher than those in non-dialysis patients, and ghrelin levels decreased with the progress of endoscopic gastric mucosal atrophy in HD patients (Table 3)[19]. Importantly, acyl-ghrelin levels in the non-*H. pylori* infection HD group (39.4 ± 23.0 fmol/mL) were significantly higher than in patients with current (24.6 ± 17.5 fmol/mL, *P* = 0.022) and past *H. pylori* infection (23.4 ± 19.9 fmol/mL, *P* = 0.007) (Table 4)[18], suggesting that the severity of serological and endoscopic gastric mucosal atrophy is a major determinant of ghrelin levels (Table 3). In fact, multiple regression analysis shows a significant positive correlation between acyl ghrelin and PG I levels ( = 0.738, *P* < 0.001) and significant negative correlations between ghrelin and age, albumin, and creatinine levels[19]. Therefore, PG level is the most influential determinant of plasma acyl and des-acyl ghrelin levels in HD patients. This suggests that plasma and gastric mucosal ghrelin levels are influenced by not only long-standing enhanced gastric mucosal inflammation induced by *H. pylori* infection but also by gastric mucosal atrophy[79]. Because plasma and gastric ghrelin levels depend on the number of ghrelin immunoreactive cells in the gastric mucosa[79-81], plasma ghrelin levels may be influenced more by the severity of atrophy than current *H. pylori* infection in HD patients. Therefore, it is important to consider methods to prevent progression of gastric mucosal atrophy in HD patients.

HD patients with gastric mucosal atrophy have a lower normalized protein catabolic rate (nPCR) than non-atrophy patients[19]. Chronic persistent damage to the gastric mucosa and gastric mucosal atrophy in *H. pylori*-positive HD patients may contribute to decreased protein intake, PEW, and decreased body weight *via* decreased ghrelin production. Because ghrelin level is associated with mortality related to cardiovascular disease and PEW in HD patients, alternative management, such as *H. pylori* eradication therapy, before the progression of gastric mucosal atrophy might be necessary to prevent the decrease in ghrelin level in HD patients[74,78].

*H. PYLORI* ERADICATION THERAPY AND NUTRITION STATUS IN HD PATIENTS

*H. pylori* infection affects the incident rate of gastro­duodenal disease and nutritional status[20,25]. *H. pylori* eradication therapy often causes individuals with normal renal function to develop hyperlipidemia and hyperproteinaemia, along with an increase of body weight and BMI[80]. This phenomenon is considered to be due to increases in plasma ghrelin level followed by increased appetite and food intake after *H. pylori* eradication therapy[82,83] In CAPD patients, *H. pylori* eradication therapy significantly improves anorexia, inflammation, and malnutrition[84]. After *H. pylori* eradication, CAPD patients with anorexia showed a significant increase in markers of nutrition and in VAS scores for almost all questions. Significant differences were also found in lymphocyte count, nPCR, prealbumin, albumin, CRP, before-lunch desire to eat, after-lunch desire to eat, hunger before lunch, hunger after lunch, fullness before lunch, consumption after lunch, and palatability[85]. However, it is unclear whether nutritional disorders in HD patients improve after eradication therapy. It is important to answer this clinical question to improve the poor prognosis in HD patients.

At 1 year after eradication therapy, serum choli­nesterase levels significantly increase compared with the level before eradication (303.2 ± 76.0 *vs* 287.3 ± 68.1 IU/L, *P* = 0.029). In particular, cholesterol (before, 196.6 ± 23.2 mg/dL; after, 206.1 ± 25.9 mg/dL, *P* = 0.042) and cholinesterase levels (before, 296.9 ± 70.8 IU/L; after, 316.4 ± 73.8 IU/L, *P* = 0.049) increase more in patients with mild-moderate gastric mucosal atrophy than in those with severe atrophy. This observation suggests that eradication therapy has contributed to improvement of PEW in HD patients. We therefore recommend that HD patientsbe checked for *H. pylori* infection and that eradication therapy should be initiated before the progression of gastric atrophy.

It is possible that the improvement in nutritional status and increase in BMI after eradication therapy depends not only on an increase in ghrelin levels but also on another biological mechanism(s), such as an improvement in gastrointestinal motility[86], change in gut microbiome profile[87], and/or increase in absorption ability[88]. Betrapally *et al*[87] reported that alterations to the intestinal microbiota affect the development of nonalcoholic steatohepatitis by influencing digestion, de­velopment of obesity, immune response, and production of gut hormones. *H. pylori* eradication therapy changes the gastrointestinal microbiota[89]. A study to examine whether the long-term prognosis of HD patients is improved by the effect of eradication therapy on the microbiota will be required to investigate this hypothesis further.

*H. PYLORI* AND ANEMIA IN HEMODIALYSIS PATIENTS

*H pylori* has been identified as a possible cause of vitamin B12 and iron deficiency in the general population. Trimarchi *et al*[90] reported that *H. pylori*-positive HD patients may present with lower vitamin B12 blood levels and that *H. pylori* should be suspected in HD patients when low or low-normal vitamin B12 levels or macrocytosis exist.

CONCLUSION

Chronic renal failure patients receiving HD have a low prevalence of *H. pylori* infection. More than one-third of patients receiving < 4 year of dialysis had naturally cured *H. pylori* infection within the 4 year observation period. However, because chronic renal failure patients have a higher risk of gastroduodenal disorders, all HD patients are recommended to receive endoscopic check-ups to reduce the chance of developing peptic ulcer disease. Moreover, patients with *H. pylori* infection should also receive eradication therapy including AMPC 250 mg twice daily to prevent peptic ulcer, gastric cancer, and hemorrhage from gastroduodenal lesions. QOL in HD patients is usually poor and affects their nutritional status. Severity of gastric atrophy is shown to be the major determinant of ghrelin levels in HD patients and eradication treatment of *H. pylori* improves nutrition status by increasing serum cholinesterase and cholesterol levels. *H. pylori* eradication before progress of gastric atrophy may be required to prevent a decrease in ghrelin levels and improve prognosis of HD patients in relation to poor nutritional status.

REFERENCES

1 **Prasad N**, Jha V. Hemodialysis in Asia. *Kidney Dis* (Basel) 2015; **1**: 165-177 [PMID: 27536677 DOI: 10.1159/000441816]

2 **Lysaght MJ**. Maintenance dialysis population dynamics: current trends and long-term implications. *J Am Soc Nephrol* 2002; **13** Suppl 1: S37-S40 [PMID: 11792760]

3 **Ala-Kaila K**. Upper gastrointestinal findings in chronic renal failure. *Scand J Gastroenterol* 1987; **22**: 372-376 [PMID: 3296137]

4 **Sezer S**, Ibiş A, Ozdemir BH, Ozdemir FN, Külah E, Boyacioğlu S, Haberal M. Association of helicobacter pylori infection with nutritional status in hemodialysis patients. *Transplant Proc* 2004; **36**: 47-49 [PMID: 15013297]

5 **Sotoudehmanesh R**, Ali Asgari A, Ansari R, Nouraie M. Endoscopic findings in end-stage renal disease. *Endoscopy* 2003; **35**: 502-505 [PMID: 12783348 DOI: 10.1055/s-2003-39672]

6 **Tsai CJ**, Hwang JC. Investigation of upper gastrointestinal hemorrhage in chronic renal failure. *J Clin Gastroenterol* 1996; **22**: 2-5 [PMID: 8776085]

7 **Khedmat H**, Ahmadzad-Asl M, Amini M, Lessan-Pezeshki M, Einollahi B, Pourfarziani V, Naseri MH, Davoudi F. Gastro-duodenal lesions and Helicobacter pylori infection in uremic patients and renal transplant recipients. *Transplant Proc* 2007; **39**: 1003-1007 [PMID: 17524875 DOI: 10.1016/j.transproceed.2007.03.034]

8 **Neithercut WD**, Rowe PA, el Nujumi AM, Dahill S, McColl KE. Effect of Helicobacter pylori infection on intragastric urea and ammonium concentrations in patients with chronic renal failure. *J Clin Pathol* 1993; **46**: 544-547 [PMID: 8331178]

9 **Block GA**, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int* 2007; **71**: 438-441 [PMID: 17200680]

10 **Nakamura S**, Sasaki O, Nakahama H, Inenaga T, Kawano Y. Clinical characteristics and survival in end-stage renal disease patients with arteriosclerosis obliterans. *Am J Nephrol* 2002; **22**: 422-428 [PMID: 12381939]

11 **Gür G**, Boyacioglu S, Gül C, Turan M, Gürsoy M, Baysal C, Ozdemir N. Impact of Helicobacter pylori infection on serum gastrin in haemodialysis patients. *Nephrol Dial Transplant* 1999; **14**: 2688-2691 [PMID: 10534513]

12 **Asaka M**, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. *Helicobacter* 2010; **15**: 1-20 [PMID: 20302585]

13 **Malfertheiner P**, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

14 **Suzuki H**, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. *J Gastroenterol* 2018; **53**: 354-361 [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1]

15 **Pellicano R**, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. *Panminerva Med* 2016; **58**: 304-317 [PMID: 27716738]

16 **Ikizler TA**, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K, Kuhlmann MK, Stenvinkel P, TerWee P, Teta D, Wang AY, Wanner C; International Society of Renal Nutrition and Metabolism. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. *Kidney Int* 2013; **84**: 1096-1107 [PMID: 23698226 DOI: 10.1038/ki.2013.147]

17 **Kovesdy CP**, George SM, Anderson JE, Kalantar-Zadeh K. Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. *Am J Clin Nutr* 2009; **90**: 407-414 [PMID: 19535427 DOI: 10.3945/ajcn.2008.27390]

18 **Ichikawa H**, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Kato A, Sugimoto K, Furuta T, Andoh A, Sakao T, Yasuda H. Relationship between ghrelin, Helicobacter pylori and gastric mucosal atrophy in hemodialysis patients. *World J Gastroenterol* 2016; **22**: 10440-10449 [PMID: 28058025 DOI: 10.3748/wjg.v22.i47.10440]

19 **Sakao Y**, Sugimoto M, Ichikawa H, Sahara S, Tsuji T, Ohashi N, Kato A, Fujigaki Y, Sugimoto K, Furuta T, Sakao T, Yasuda H. Severity of Gastric Mucosal Atrophy Is the Major Determinant of Plasma Ghrelin Level in Hemodialysis Patients. *Am J Nephrol* 2016; **44**: 224-233 [PMID: 27578611 DOI: 10.1159/000449019]

20 **Sugimoto M**, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. *Kidney Int* 2009; **75**: 96-103 [PMID: 18843261]

21 **Marshall BJ**, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023]

22 **Perez-Perez GI**, Taylor DN, Bodhidatta L, Wongsrichanalai J, Baze WB, Dunn BE, Echeverria PD, Blaser MJ. Seroprevalence of Helicobacter pylori infections in Thailand. *J Infect Dis* 1990; **161**: 1237-1241 [PMID: 2345304]

23 **Sugimoto M**, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. *Clin Microbiol Infect* 2009; **15**: 835-842 [PMID: 19392900 DOI: 10.1111/j.1469-0691.2009.02769.x]

24 **Sugimoto M**, Zali MR, Yamaoka Y. The association of vacA genotypes and Helicobacter pylori-related gastroduodenal diseases in the Middle East. *Eur J Clin Microbiol Infect Dis* 2009; **28**: 1227-1236 [PMID: 19551413 DOI: 10.1007/s10096-009-0772-y]

25 **Sugimoto M**, Yamaoka Y. Review of Helicobacter pylori infection and chronic renal failure. *Ther Apher Dial* 2011; **15**: 1-9 [PMID: 21272246 DOI: 10.1111/j.1744-9987.2010.00851.x]

26 **Hirayama Y**, Kawai T, Otaki J, Kawakami K, Harada Y. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. *J Gastroenterol Hepatol* 2014; **29** Suppl 4: 16-19 [PMID: 25521727 DOI: 10.1111/jgh.12795]

27 **Sugimoto M**, Sahara S, Ichikawa H, Sakao Y, Ohashi N, Sugimoto K, Yasuda H, Furuta T, Andoh A. Natural Course of Helicobacter pylori Infection in Japanese Hemodialysis Patients. *Digestion* 2017; **95**: 302-309 [PMID: 28521319 DOI: 10.1159/000475659]

28 **Nakajima F**, Sakaguchi M, Amemoto K, Oka H, Kubo M, Shibahara N, Ueda H, Katsuoka Y. Helicobacter pylori in patients receiving long-term dialysis. *Am J Nephrol* 2002; **22**: 468-472 [PMID: 12381945]

29 **Yildiz A**, Beşişik F, Akkaya V, Sever MS, Bozfakioğlu S, Yilmaz G, Ark E. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. *Clin Transplant* 1999; **13**: 13-16 [PMID: 10081629]

30 **Muñoz de Bustillo E**, Sánchez Tomero JA, Sanz JC, Moreno JA, Jiménez I, López-Brea M, Pajares JM, Traver JA. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. *Nephron* 1998; **79**: 55-60 [PMID: 9609463]

31 **Nakajima F**, Sakaguchi M, Oka H, Kawase Y, Shibahara N, Inoue T, Ueda H, Katsuoka Y. Prevalence of Helicobacter pylori antibodies in long-term dialysis patients. *Nephrology* (Carlton) 2004; **9**: 73-76 [PMID: 15056265]

32 **Hwang IR**, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. *Gastroenterology* 2002; **123**: 1793-1803 [PMID: 12454835]

33 **Wesdorp RI**, Falcao HA, Banks PB, Martino J, Fischer JE. Gastrin and gastric acid secretion in renal failure. *Am J Surg* 1981; **141**: 334-338 [PMID: 7011077]

34 **El-Omar EM**, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. *Nature* 2000; **404**: 398-402 [PMID: 10746728]

35 **Sugimoto M**, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M, Sugimura H, Hishida A. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. *J Gastroenterol Hepatol* 2007; **22**: 51-59 [PMID: 17201881 DOI: 10.1111/j.1440-1746.2006.04442.x]

36 **Gladziwa U**, Haase G, Handt S, Riehl J, Wietholtz H, Dakshinamurty KV, Glöckner WM, Sieberth HG. Prevalence of Helicobacter pylori in patients with chronic renal failure. *Nephrol Dial Transplant* 1993; **8**: 301-306 [PMID: 8390002]

37 **Francke EL**, Appel GB, Neu HC. Kinetics of intravenous amoxicillin in patients on long-term dialysis. *Clin Pharmacol Ther* 1979; **26**: 31-35 [PMID: 445959]

38 **Yoshimura T**, Shimoyama T, Fukuda S, Tanaka M, Axon AT, Munakata A. Most gastric cancer occurs on the distal side of the endoscopic atrophic border. *Scand J Gastroenterol* 1999; **34**: 1077-1081 [PMID: 10582756]

39 **Iijima K**, Koike T, Abe Y, Shimosegawa T. Cutoff serum pepsinogen values for predicting gastric acid secretion status. *Tohoku J Exp Med* 2014; **232**: 293-300 [PMID: 24717778]

40 **Masuyama H**, Yoshitake N, Sasai T, Nakamura T, Masuyama A, Zuiki T, Kurashina K, Mieda M, Sunada K, Yamamoto H, Togashi K, Terano A, Hiraishi H. Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk. *Digestion* 2015; **91**: 30-36 [PMID: 25632914 DOI: 10.1159/000368807]

41 **Nakahama H**, Tanaka Y, Shirai D, Nishihara F, Takamitsu Y, Nakanishi T, Sugita M. Elevated serum pepsinogens in chronic renal failure patients. *Nephron* 1995; **70**: 211-216 [PMID: 7566306]

42 **Moriyama T**, Matsumoto T, Hirakawa K, Ikeda H, Tsuruya K, Hirakata H, Iida M. Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis. *J Gastroenterol* 2010; **45**: 515-522 [PMID: 20084526 DOI: 10.1007/s00535-009-0196-6]

43 **Ota K**, Yamashita N, Suzuki T, Agishi T. Malignant tumours in dialysis patients: a nationwide survey. *Proc Eur Dial Transplant Assoc* 1981; **18**: 724-730 [PMID: 7329999]

44 **Uemura N**, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. *N Engl J Med* 2001; **345**: 784-789 [PMID: 11556297]

45 **Wong BC**, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS; China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. *JAMA* 2004; **291**: 187-194 [PMID: 14722144]

46 **Hopkins RJ**, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. *Gastroenterology* 1996; **110**: 1244-1252 [PMID: 8613015]

47 **Uemura N**, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1997; **6**: 639-642 [PMID: 9264278]

48 **Wotherspoon AC**, Doglioni C, de Boni M, Spencer J, Isaacson PG. Antibiotic treatment for low-grade gastric MALT lymphoma. *Lancet* 1994; **343**: 1503 [PMID: 7911202]

49 **Sugimoto M**, Kajimura M, Shirai N, Furuta T, Kanaoka S, Ikuma M, Sato Y, Hishida A. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. *Intern Med* 2006; **45**: 405-409 [PMID: 16617193]

50 **Asaka M**, Sugiyama T, Kato M, Satoh K, Kuwayama H, Fukuda Y, Fujioka T, Takemoto T, Kimura K, Shimoyama T, Shimizu K, Kobayashi S. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. *Helicobacter* 2001; **6**: 254-261 [PMID: 11683930]

51 **Murakami K**, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J, Sato S, Abe H, Arita T. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2002; **16**: 1933-1938 [PMID: 12390102]

52 **Sugimoto M**, Uotani T, Sahara S, Ichikawa H, Yamade M, Sugimoto K, Furuta T. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. *Helicobacter* 2014; **19**: 312-318 [PMID: 24690010 DOI: 10.1111/hel.12128]

53 **Sugimoto M**, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. *Helicobacter* 2017; **22** [PMID: 27213463 DOI: 10.1111/hel.12319]

54 **Aydemir S**, Boyacioglu S, Gur G, Demirbilek M, Can FK, Korkmaz M, Yilmaz U. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. *World J Gastroenterol* 2005; **11**: 842-845 [PMID: 15682477]

55 **Sahara S,** Sugimoto M, Ichikawa H, Kagami T, Sakao Y, Ohashi N, Horio Y, Sugimoto K, Kato A, Furuta T, Yasuda H. Efficacy of reduced dosage of amoxicillin in an eradication therapy for Helicobacter pylori infection in patients on hemodialysis: a randomized controlled trial. *Digestion* 2018; **97:** 163-169[PMID: 29310119 DOI: 10.1159/000484981]

56 **Sharara AI**, Chaar HF, Aoun E, Abdul-Baki H, Araj GF, Kanj SS. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. *Helicobacter* 2006; **11**: 231-236 [PMID: 16882325]

57 **Murakami K**, Sato R, Okimoto T, Nasu M, Fujioka T, Kodama M, Kagawa J. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. *Aliment Pharmacol Ther* 2003; **17**: 119-123 [PMID: 12492740]

58 **Kawakami E**, Machado RS, Ogata SK, Langner M, Fukushima E, Carelli AP, Bonucci VC, Patricio FR. Furazolidone-based triple therapy for H pylori gastritis in children. *World J Gastroenterol* 2006; **12**: 5544-5549 [PMID: 17006997]

59 **Sugimoto M**, Sahara S, Ichikawa H, Kagami T, Uotani T, Furuta T. High Helicobacter pylori cure rate with sitafloxacin-based triple therapy. *Aliment Pharmacol Ther* 2015; **42**: 477-483 [PMID: 26075959 DOI: 10.1111/apt.13280]

60 **Siddique O**, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: an Update for the Internist in the Age of Increasing Global Antibiotic Resistance. *Am J Med* 2018; Epub ahead of print [PMID: 29353050 DOI: 10.1016/j.amjmed.2017.12.024]

61 **Tamura H**, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Sekine S, Hirose H, Mitarai T, Isoda K. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. *Am J Kidney Dis* 1997; **29**: 86-90 [PMID: 9002534]

62 **Tokushima H**, Tamura H, Murakawa M, Matsumura O, Itakura Y, Itoyama S, Mitarai T, Isoda K. Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease. *Intern Med* 1998; **37**: 435-439 [PMID: 9652896]

63 **Araki H**, Miyazaki R, Matsuda T, Gejyo F, Koni I. Significance of serum pepsinogens and their relationship to Helicobacter pylori infection and histological gastritis in dialysis patients. *Nephrol Dial Transplant* 1999; **14**: 2669-2675 [PMID: 10534510]

64 **Wang YL**, Sheu BS, Huang JJ, Yang HB. Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. *Am J Kidney Dis* 2001; **38**: 98-103 [PMID: 11431188]

65 **Tsukada K**, Miyazaki T, Katoh H, Masuda N, Ojima H, Fukai Y, Nakajima M, Manda R, Fukuchi M, Kuwano H, Tsukada O. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. *Scand J Gastroenterol* 2002; **37**: 1265-1268 [PMID: 12465723]

66 **Arancibia A**, Drouguett MT, Fuentes G, González G, González C, Thambo S, Palombo G. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. *Int J Clin Pharmacol Ther Toxicol* 1982; **20**: 447-453 [PMID: 7141752]

67 **Jones DP**, Gaber L, Nilsson GR, Brewer ED, Stapleton FB. Acute renal failure following amoxicillin overdose. *Clin Pediatr* (Phila) 1993; **32**: 735-739 [PMID: 8275607]

68 **Sheu BS**, Huang JJ, Yang HB, Huang AH, Wu JJ. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. *Aliment Pharmacol Ther* 2003; **17**: 1283-1290 [PMID: 12755841]

69 **Itatsu T**, Miwa H, Nagahara A, Kubota M, Miyazaki A, Sato N, Hayashida Y. Eradication of Helicobacter pylori in hemodialysis patients. *Ren Fail* 2007; **29**: 97-102 [PMID: 17365917]

70 **Chang WC**, Jo YI, Park HS, Jegal J, Park JH, Lee JH, Jin CJ. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. *Clin Exp Nephrol* 2010; **14**: 469-473 [PMID: 20632062 DOI: 10.1007/s10157-010-0319-7]

71 **Mak RH**, Cheung WW. Is ghrelin a biomarker for mortality in end-stage renal disease? *Kidney Int* 2011; **79**: 697-699 [PMID: 21403653 DOI: 10.1038/ki.2010.520]

72 **Fouque D**, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Treviño-Becerra A, Wanner C. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Kidney Int* 2008; **73**: 391-398 [PMID: 18094682 DOI: 10.1038/sj.ki.5002585]

73 **Kojima M**, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999; **402**: 656-660 [PMID: 10604470 DOI: 10.1038/45230]

74 **Carrero JJ**, Nakashima A, Qureshi AR, Lindholm B, Heimbürger O, Bárány P, Stenvinkel P. Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. *Kidney Int* 2011; **79**: 749-756 [PMID: 21178976 DOI: 10.1038/ki.2010.487]

75 **Pradhan G**, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. *Curr Opin Clin Nutr Metab Care* 2013; **16**: 619-624 [PMID: 24100676 DOI: 10.1097/MCO.0b013e328365b9be]

76 **Akamizu T**, Kangawa K. Ghrelin for cachexia. *J Cachexia Sarcopenia Muscle* 2010; **1**: 169-176 [PMID: 21475698 DOI: 10.1007/s13539-010-0011-5]

77 **Ariyasu H**, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. *J Clin Endocrinol Metab* 2001; **86**: 4753-4758 [PMID: 11600536 DOI: 10.1210/jcem.86.10.7885]

78 **Chou CC**, Bai CH, Tsai SC, Wu MS. Low serum acylated ghrelin levels are associated with the development of cardiovascular disease in hemodialysis patients. *Intern Med* 2010; **49**: 2057-2064 [PMID: 20930430]

79 **Osawa H**, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugano K. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. *J Clin Endocrinol Metab* 2005; **90**: 10-16 [PMID: 15483107 DOI: 10.1210/jc.2004-1330]

80 **Osawa H**, Kita H, Ohnishi H, Nakazato M, Date Y, Bowlus CL, Ishino Y, Watanabe E, Shiiya T, Ueno H, Hoshino H, Satoh K, Sugano K. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. *J Gastroenterol* 2006; **41**: 954-961 [PMID: 17096064 DOI: 10.1007/s00535-006-1880-4]

81 **Suzuki H**, Masaoka T, Hosoda H, Ota T, Minegishi Y, Nomura S, Kangawa K, Ishii H. Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. *Gut* 2004; **53**: 187-194 [PMID: 14724148]

82 **Furuta T**, Shirai N, Xiao F, Takashima M, Hanai H. Effect of Helicobacter pylori infection and its eradication on nutrition. *Aliment Pharmacol Ther* 2002; **16**: 799-806 [PMID: 11929399]

83 **Jang EJ**, Park SW, Park JS, Park SJ, Hahm KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, Baik HW. The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. *J Gastroenterol Hepatol* 2008; **23** Suppl 2: S278-S285 [PMID: 19120912 DOI: 10.1111/j.1440-1746.2008.05415.x]

84 **Kawashima J**, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S, Kato S, Yakabi K. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. *J Gastroenterol* 2009; **44**: 1046-1054 [PMID: 19701601 DOI: 10.1007/s00535-009-0120-0]

85 **Aguilera A**, Codoceo R, Bajo MA, Diéz JJ, del Peso G, Pavone M, Ortiz J, Valdez J, Cirugeda A, Fernández-Perpén A, Sánchez-Tomero JA, Selgas R. Helicobacter pylori infection: a new cause of anorexia in peritoneal dialysis patients. *Perit Dial Int* 2001; **21** Suppl 3: S152-S156 [PMID: 11887811]

86 **Zhang CL**, Geng CH, Yang ZW, Li YL, Tong LQ, Gao P, Gao YQ. Changes in patients’ symptoms and gastric emptying after Helicobacter pylori treatment. *World J Gastroenterol* 2016; **22**: 4585-4593 [PMID: 27182168 DOI: 10.3748/wjg.v22.i18.4585]

87 **Betrapally NS**, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? *Gastroenterology* 2016; **150**: 1745-1755.e3 [PMID: 26948887 DOI: 10.1053/j.gastro.2016.02.073]

88 **Serin E**, Gümürdülü Y, Ozer B, Kayaselçuk F, Yilmaz U, Koçak R. Impact of Helicobacter pylori on the development of vitamin B12 deficiency in the absence of gastric atrophy. *Helicobacter* 2002; **7**: 337-341 [PMID: 12485119]

89 **Li L**, Zhou X, Xiao S, Ye F, Zhang G. The Effect of Helicobacter pylori Eradication on the Gastrointestinal Microbiota in Patients with Duodenal Ulcer. *J Gastrointestin Liver Dis* 2016; **25**: 139-146 [PMID: 27308643 DOI: 10.15403/jgld.2014.1121.252.hpe]

90 **Trimarchi H**, Forrester M, Schropp J, Pereyra H, Freixas EA. Low initial vitamin B12 levels in Helicobacter pylori--positive patients on chronic hemodialysis. *Nephron Clin Pract* 2004; **96**: c28-c32 [PMID: 14752251 DOI: 10.1159/000075569]

91 **Mak SK**, Loo CK, Wong AM, Wong PN, Lo KY, Tong GM, Lam EK, Wong AK. Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure. *Am J Kidney Dis* 2002; **40**: 576-581 [PMID: 12200810]

92 **Mak SK**, Loo CK, Wong PN, Lo KY, Tong GM, Lam EK, Wong AK. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure. *Singapore Med J* 2003; **44**: 74-78 [PMID: 14503780]

93 **Tseng GY**, Lin HJ, Fang CT, Yang HB, Tseng GC, Wang PC, Hung TL, Deng YC, Cheng YT, Huang CH. Recurrence of peptic ulcer in uraemic and non-uraemic patients after Helicobacter pylori eradication: a 2-year study. *Aliment Pharmacol Ther* 2007; **26**: 925-933 [PMID: 17767477]

94 **Jalalzadeh M**, Saber HR, Vafaeimanesh J, Mirzamohammadi F, Falaknazi K. Association of Helicobacter pylori infection and serum albumin in patients on hemodialysis. *Iran J Kidney Dis* 2010; **4**: 312-316 [PMID: 20852373]

95 **Falaknazi K**, Jalalzadeh M, Vafaeimanesh J. Noninvasive stool antigen assay for screening of Helicobacter pylori infection and assessing success of eradication therapy in patients on hemodialysis. *Iran J Kidney Dis* 2010; **4**: 317-321 [PMID: 20852374]

96 **Seyyedmajidi M**, Falaknazi K, Mirsattari D, Zojaji H, Roshani M, Lahmi F, Orimi PG, Hadizadeh M, Zali M. Correlation between creatinine clearance and Helicobacter pylori infection eradication with sequential and triple therapeutic regimens: A randomised clinical trial. *Arab J Gastroenterol* 2011; **12**: 150-153 [PMID: 22055594 DOI: 10.1016/j.ajg.2011.07.004]

97 **Jalalzadeh M**, Ghadiani MH, Mousavinasab N. Association between helicobacter pylori infection and body mass index, before and after eradication of infection in hemodialysis batients. *J Nephropathol* 2012; **1**: 170-176 [PMID: 24475411 DOI: 10.5812/nephropathol.8115]

98 **Jalalzadeh M**, Nazarian M, Vafaeimanesh J, Mirzamohammadi F. Comparison of azithromycin and clarithromycin triple therapy regimens for helicobacter pylori eradication in hemodialysis patients. *Nephrourol Mon* 2012; **4**: 571-577 [PMID: 23573488 DOI: 10.5812/numonthly.2794]

99 **Vafaeimanesh J**, Jalalzadeh M, Nazarian M. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. *Saudi J Kidney Dis Transpl* 2014; **25**: 53-57 [PMID: 24434382]

100 **Makhlough A**, Fakheri H, Farkhani AR, Seddighi O, Hossieni SV, Khademloo M, Bari Z. A comparison between standard triple therapy and sequential therapy on eradication of Helicobacter pylori in uremic patients: A randomized clinical trial. *Adv Biomed Res* 2014; **3**: 248 [PMID: 25590026 DOI: 10.4103/2277-9175.146372]

101 **Makhlough A**, Fakheri H, Hojati S, Hosseini V, Bari Z. A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial. *Middle East J Dig Dis* 2016; **8**: 39-43 [PMID: 26933480 DOI: 10.15171/mejdd.2016.05]

Footnotes

Manuscript source: Invited manuscript

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

Conflict-of-interest statement: No potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Peer-review started: February 23, 2018

First decision: March 15, 2018

Article in press: March 25, 2018

**P- Reviewer**: Papamichail K, Paoluzi OA, Pellicano R, Slomiany BL **S- Editor**:Wang XJ **L- Editor**: A **E- Editor**:Huang Y

**Table 1 Hemodialysis treatment duration and *Helicobacter pylori* infection status in hemodialysis patients[27], %**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | < 1 yr | 1-3 yr | 3-10 yr | > 10 yr | *P* value |
| *H. pylori* infection rate | 23.8 (15/63) | 16.7 (18/108) | 15.0 (34/226) | 7.8 (8/13) | 0.043 |
| Rate of *H. pylori* negatives | 55.5 (35/63) | 62.0 (67/108) | 68.1 (154/226) | 68.9 (71/103) | > 0.05 |

**Table 2 *Helicobacter pylori* eradication therapy for chronic renal failure patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Year** | **Author** | **Country** | ***n*** | **Regimen** | **Treatment period** | **Eradication rate (%)** | **Analytic methods** |
| 1997 | Tamura *et al*[61] | Japan | 14 | LPZ (30) oid/ 8 wk, AMPC (500) oid/ 3 wk, plaunotol (80) tid/ 24 wk | 21 d | 78.6 | RUT, Culture, Histology |
| 1998 | Munos de Bustillo E *et al*[30] | Spain | 23 | OPZ (20) bid, AMPC (500) tid | 14 d | 60.8 | UBT |
| 23 | plus OPZ (20) bid, CAM (500) bid | 14 d | 82.6 |  |
| 1998 | Tokushima *et al*[62] | Japan | 17 | LPZ (30) oid/ 8 wk, AMPC (500) | 21 d | 76.5 | RUT, Culture, Histology |
| 10 | LPZ (30) oid, AMPC (250), MNZ (250) bid/ | 7 d | 90 |  |
| 1999 | Araki *et al*[63] | Japan | 17 | OPZ (20) oid/ 8 wk, AMPC (250) oid, CAM (200) oid/ 3 wk, polaprizinc (0.5) bid/ 24 wk | 21 d | 88.2 | IgG, Histology |
| 1999 | Gur *et al*[11] | Turkey | 25 | FAM (40) oid, CAM (500) bid, MNZ (250) bid | 15 d | 80 | Histology, RUT |
| 2001 | Wang *et al*[64] | China | 38 | OPZ (20), AMPC (1000), CAM (500) bid | 7 d | 86.8 | Stool |
| 2002 | Mak *et al*[91] | China | 21 (CRF) | OPZ (20), AMPC (1000), CAM (500) bid | 7 d | 90.5 | RUT |
| 2002 | Tsukada *et al*[65] | Japan | 39 | OPZ (30) bid, AMPC (500) tid, CAM (400) bid | 7 d | 82.1 | UBT |
| 2003 | Mak *et al*[92] | China | 25 (CRF) | OPZ (20) or LPZ (30), AMPC (1000), CAM (500) bid | 7 d | 96 | Histology |
| 2003 | Sheu *et al*[67] | China | 38 (CRF) | LPZ (30), AMPC (750), CAM (500) bid | 7 d | 76.3 |  |
| 40 (CRF) | LPZ (30), CAM (500), MNZ (500) bid | 7 d | 92.5 | Stool |
| 2004 | Sezer *et al*[4] | Turkey | 17 | OPZ (20), AMPC (1000), CAM (500) bid/ | 14 d | 94.1 | Endoscopy |
| 2007 | Tseng *et al*[93] | China | 34 (CRF) | ESO (40) or OPZ (20) bid, AMPC (1000) bid, CAM (500) bid | 7 d | 94.1 | UBT |
| 2007 | Itatsu *et al*[69] | Japan | 11 | LPZ (60), AMPC (750), CAM (400) | 7 d | 72.7 | RUT |
|  |  |  | 9 | LPZ (60), CAM (400) | 7 d | 33.3 |  |
| 2010 | Change *et al*[70] | Korea | 12 | OPZ (20), AMPC (250), CAM (250), bid | 7 d | 83.4 | RUT, Histology |
| 2010 | Jalalzadeh *et al*[94], Falaknazi *et al*[95] | Iran | 37 | OPZ (20), AMPC (1000), CAM (250), bid | 14 d | 81.1 | IgG, UBT, Stool |
| 2012 | Seyyedmajidi *et al*[96], Jalalzadeh *et al*[97,98] | Iran | 17 | OPZ (20), AMPC (500), CAM (250), bid | 14 d | 82.4 | UBT, Stool |
| Vafaeimanesh *et al*[99] |
| 20 | OPZ (40), AMPC (500), azithromycin (250), bid | 14 d | 80 |  |
| 2014 | Makhlough *et al*[100] | Iran | 21 | PPZ (40), AMPC (500), CAM (250), bid | 14 d | 66.7 | RUT, Histology |
| 24 | Sequential therapy (PPT [40] 10 d, AMPC (500) bid, 5 d and CAM (250), tinidazole (500), bid, 5 d | 10 d | 84 |  |
| 2016 | Makhlough *et al*[101] | Iran | 20 | PPZ (40), AMPC (500), CAM (500), bid | 14 d | 70 | RUT, Stool |
| 20 | Hybrid regimen PPZ (40), AMPC (500), bid, 7 d + PPZ (40), AMPC (500), CAM (500), tinidazole (500), bid, 7 d | 14 d | 100 |  |
| 2018 | Sahara *et al*[55] | Japan | 18 | ESO (20), AMPC (750), CAM (200) bid | 7 d | 77.8 | IgG |
| 19 | ESO (20), AMPC (250), CAM (200) bid | 7 d | 84.2 |  |

AMPC: Amoxicillin; CAM: Clarithromycin; ESO: Esomeprazole; FAM: Famotidine; LPZ: Lansoprazole; MNZ: Metronidazole; NA: Not available; OPZ: Omeprazole; PPZ: Pantoprazole; RUT: Rapid urease test; UBT: Urea breath test; bid: Twice-daily dosing; tid: Three-times-daily dosing.

**Table 3 Clinical characteristics in hemodialysis patients between patients with and without gastric mucosal atrophy[19]**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Atrophy (-)** | **Atrophy (+)** | ***P*-value** |
| N (Male/Female) | 28 (17/11) | 50 (33/17) | - |
| Age  | 67.7 ± 12.3 | 71.6 ± 11.0 | 0.155 |
| Dialysis periods (yr) | 7.5 (2.4-16.8) | 7.7 (3.1-12.7) | 0.681 |
| Acyl-ghrelin | 38.0 (23.5-57.0) | 18.0 (12.0-26.3) | < 0.001 |
| Desacyl-ghrelin | 303 (248-533) | 200 (137-277) | < 0.001 |
| BMI (kg/m2) | 19.8 ± 3.2 | 19.6 ± 2.8 | 0.773 |
| Albumin (g/dL) | 3.5 ± 0.3 | 3.4 ± 0.4 | 0.273 |
| Total cholesterol (mg/dL) | 166 ± 37 | 154 ± 36 | 0.165 |
| Cholinesterase (U/L) | 245 ± 111 | 219 ± 68.7 | 0.205 |
| Intact PTH (pg/mL) | 351 ± 294 | 247 ± 192 | 0.062 |
| Ferritin (ng/mL) | 128 ± 118 | 128 ± 221 | 0.989 |
| PG Ⅰ (ng/mL) | 416.2 (314.2-783.7) | 196.0 (73.8-358.8) | < 0.001 |
| PG Ⅱ (ng/mL) | 42.3 (31.6-60.0) | 28.4 (16.8-45.7) | 0.003 |
| PG Ⅰ/Ⅱ ratio | 10.89 (9.11-13.38) | 7.31 (4.17-11.08) | 0.001 |
| nPCR (g/kg/d) | 0.94 ± 0.14 | 0.85 ± 0.16 | 0.022 |

BMI: Body mass index; BUN: Blood urea nitrogen; PTH: Parathyroid hormone; CRP: C-reactive protein; PG: Pepsinogen; ABI: Ankle-brachial pressure index; nPCR: Normalized protein catabolic rate.

**Table 4 Plasma acyl-ghrelin and desacyl-ghrelin levels according to *Helicobacter pylori* status in hemodialysis patients[18]**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-infection (*n* = 29)** | **Past-infection (*n* = 27)** | **Present infection (*n* = 17)** |
| Plasma acyl-ghrelin (fmol/mL) | 39.4 ± 23.0 | 23.4 ± 19.9a | 24.6 ± 17.5a |
| Plasma desacyl-ghrelin (fmol/mL) | 353.2 ± 190.2 | 242.1 ± 139.6a | 236.3 ± 143.6a |

a*P* < 0.05 *vs* Non-infection group.